University Hospital La Timone, Department of Neurology and Neuropsychology
Welcome,         Profile    Billing    Logout  
 4 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ceccaldi, Mathieu
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NanoLi®_AD, NCT05423522 / 2021-001273-23: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

Completed
2
72
Europe
NanoLithium® NP03, Placebo
Medesis Pharma SA, MEDESIS Pharma SA
Alzheimer's Disease
01/24
10/24
EvaMMADom, NCT03360552: Evaluating the Effectiveness of a New Way of Organizing Primary Health Care to Improve the Management of Alzheimer's Disease

Recruiting
N/A
320
Europe
Multidimensional fragility index questionnaire RAI-Home Care, Usual care
Assistance Publique Hopitaux De Marseille
Alzheimer's Disease
01/26
01/26
Pelat, Julie
FTD-GRN, NCT04408625 / 2019-003159-12: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations

Recruiting
1/2
30
Europe, US, RoW
LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone
Prevail Therapeutics, Eli Lilly and Company
Frontotemporal Dementia
08/29
08/29

Download Options